Arden forecast
This article was originally published in The Rose Sheet
Executive Summary
Elizabeth Arden predicts Q1 sales decline due to impact of Severe Acute Respiratory Syndrome, which adversely effected firm's sales in travel retail and certain international markets, fragrance distributor announces May 19. Sales projected in $133 mil.-$135 mil. range in the period compared to $140.3 mil. a year ago. Arden also expects to report net loss of $.92-$.94 per share, firm adds. Initial guidance for the year assumed some degree of caution due to the challenging retail environment, Arden says, noting it still expects to achieve net sales guidance of 5%-7% and EPS growth of 20%-25% for the full fiscal year. However, "if the SARS epidemic and the softness experienced with U.S. retailers continue to create an adverse retail environment for the remainder of the year," results likely will be negatively impacted, Arden cautions...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.